Integrated Diagnostics Holdings plc (IDGXF)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in EGP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | EGP m | 2,656 | 5,225 | 3,605 | 4,123 | 5,720 | 7,855 | 9,169 | 9,627 |
| Operating profit | EGP m | 2,125 | 2,577 | ||||||
| Net profit | EGP m | 594 | 1,413 | 541 | 510 | 1,077 | 1,262 | 1,532 | 1,590 |
| EPS reported | EGP | 2.17 | 2.59 | ||||||
| Operating cashflow per share | EGP | 3.28 | 0.34 | ||||||
| Capex per share | EGP | 0.90 | 0.10 | ||||||
| FCF per share | EGP | 2.38 | 0.24 | ||||||
| Free cash flow | EGP m | 1,383 | 0 | ||||||
| Net debt | EGP m | -1,698 | -1,587 | ||||||
| Book value equity | EGP m | 3,383 | 3,925 | ||||||
| Book value per share | EGP | 5.82 | 6.75 | ||||||
| Number of shares | m | 581.33 | 581.33 | ||||||
| DPS (TTM paid) | EGP | 1.29 | 0.45 |
Financial summary
Financials in EGP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 15.24 | 11.28 | ||||||
| P/B LTM | x | 5.57 | 4.80 | ||||||
| P/S LTM | x | 2.40 | 2.05 | ||||||
| P/FCF LTM | x | 13.62 | 109.75 | ||||||
| EV/EBITDA LTM | x | 6.49 | 6.50 | ||||||
| EV/Sales LTM | x | 2.39 | 1.89 | ||||||
| Earnings Yield LTM | % | +6.56% | +8.87% | ||||||
| FCF Yield | % | +7.34% | 0.00% | ||||||
| Quality | |||||||||
| ROE | % | +37.31% | +38.79% | ||||||
| ROIC | % | +20.67% | 0.00% | ||||||
| Operating margin | % | +27.05% | +26.55% | ||||||
| Gross margin | % | +42.69% | +41.88% | ||||||
| FCF/Sales | % | +17.61% | +1.72% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +19.23% | +42.31% | ||||||
| Sales Growth YoY | % | +37.34% | +60.30% | ||||||
| Net Income Growth YoY | % | +17.15% | +42.23% | ||||||
| FCF Growth | % | +2.93% | -100.00% | ||||||
| Operating Profit Growth | % | +74.95% | +112.25% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +2.84% | +4.92% | ||||||
| Dividend Growth | % | +2689.0% | +881.40% | ||||||
| Payout Ratio | % | +42.42% | +0.09% | ||||||
| FCF/Debt | x | 0.86 | 0.00 | ||||||
| Net Debt/EBITDA | x | -0.02 | 0.00 | ||||||
| EBIT/Net interest | x | 10.19 | 0.00 | ||||||
| Net debt/market cap | % | +2.27% | 0.00% | ||||||
| Net debt/Equity | x | -0.50 | -0.40 | ||||||
| Gross debt/equity | x | 0.48 | 0.43 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Integrated Diagnostics Holdings plc (IDGXF) functions as a consumer-focused healthcare enterprise, primarily dedicated to providing a comprehensive array of medical diagnostic services for patients. Its extensive service portfolio encompasses approximately 2,000 distinct diagnostic examinations, spanning diverse fields such as immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, cytogenetics, histopathology, and radiology. The company maintains an operational footprint across Egypt, Jordan, Sudan, and Nigeria. By December 30, 2021, its network had grown to encompass 452 branch laboratories. Established in 1979, the organization's main office is situated in Saint Helier, Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Integrated Diagnostics Holdings plc (IDGXF)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Integrated Diagnostics Holdings plc (IDGXF) functions as a consumer-focused healthcare enterprise, primarily dedicated to providing a comprehensive array of medical diagnostic services for patients. Its extensive service portfolio encompasses approximately 2,000 distinct diagnostic examinations, spanning diverse fields such as immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, cytogenetics, histopathology, and radiology. The company maintains an operational footprint across Egypt, Jordan, Sudan, and Nigeria. By December 30, 2021, its network had grown to encompass 452 branch laboratories. Established in 1979, the organization's main office is situated in Saint Helier, Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free